GENX — Genex Pharmaceutical Income Statement
0.000.00%
HealthcareHighly SpeculativeMicro Cap
Annual income statement for Genex Pharmaceutical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2003 December 31st | 2004 December 31st | 2005 December 31st | 2006 December 31st | 2007 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10KSB | 10KSB | 10KSB | 10KSB | 10KSB |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1.22 | 2.35 | 2.49 | 2.44 | 3.24 |
Cost of Revenue | |||||
Gross Profit | 1.01 | 2.07 | 2.19 | 2.22 | 2.87 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 0.778 | 1.36 | 1.57 | 1.59 | 2.77 |
Operating Profit | 0.444 | 0.992 | 0.921 | 0.847 | 0.466 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 0.451 | 1.01 | 0.954 | 1.03 | 0.734 |
Provision for Income Taxes | |||||
Net Income After Taxes | 0.451 | 1.01 | 0.626 | 0.619 | 0.343 |
Net Income Before Extraordinary Items | |||||
Net Income | 0.451 | 1.01 | 0.626 | 0.619 | 0.343 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 0.451 | 1.01 | 0.626 | 0.619 | 0.343 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.031 | 0.057 | 0.035 | 0.035 | 0.019 |
Dividends per Share |